MARC Record from marc_columbia

LEADER: 03058mam a2200433 a 4500
001 4063973
005 20221027030258.0
008 991215s2001 njua b 001 0 eng c
010 $a 99089543
015 $aGBA0-Y6895
020 $a0896036685 (alk. paper)
035 $a(OCoLC)ocm43095606
035 $9ARR2766HS
035 $a(NNC)4063973
035 $a4063973
040 $aNLM$cNLM$dUKM$dNNC-M$dOrLoB-B
042 $apcc
060 10 $aQU 136$bM4338 2000
082 04 $a612.01516$221
245 00 $aMatrix metalloproteinase inhibitors in cancer therapy /$cedited by Neil J. Clendeninn and Krzysztof Appelt.
260 $aTotowa, N.J. :$bHumana Press,$c2001.
300 $axi, 262 pages :$billustrations (some color) ;$c24 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aCancer drug discovery and development
504 $aIncludes bibliographical references and index.
505 00 $g1.$tBiology and Regulation of the Matrix Metalloproteinases /$rMark D. Sternlicht, Lisa M. Coussens and Thiennu H. Vu /$r[et al.] --$g2.$tSubstrate Specificity of MMPs /$rHideaki Nagase --$g3.$tThe Tissue Inhibitors of Metalloproteinases (TIMPs): Biology and Regulation /$rDylan R. Edwards --$g4.$tMatrix Metalloproteinases in Cancer /$rBarbara Fingleton and Lynn M. Matrisian --$g5.$tHydroxamic Acid Matrix Metalloproteinase Inhibitors /$rPeter D. Brown, Alan H. Davidson and Alan H. Drummond /$r[et al.] --$g6.$tPrinomastat: A Potent and Selective Matrix Metalloprotease Inhibitor - Preclinical and Clinical Development for Oncology /$rDavid R. Shalinsky, Bhasker Shetty and Yazdi Pithavala /$r[et al.] --$g7.$tA Potent Nonpeptidic Matrix Metalloproteinase Inhibitor: Discovery of BAY 12-9566 /$rGeorge Clemens, Barbara Hibner and Rachel Humphrey /$r[et al.] --$g8.$tD1927 and D2163: Novel Mercaptoamide Inhibitors of Matrix Metalloproteinases /$rA. D. Baxter, J. B. Bird and R. Bannister /$r[et al.] --
505 80 $g9.$tResearch on MMP Inhibitors with Unusual Scaffolds /$rFrank Grams, Hans Brandstetter and Richard A. Engh /$r[et al.] --$g10.$tMatrix Metalloproteinase Inhibitors: Therapeutic Applications Outside of Oncology /$rMichael R. Niesman.
650 12 $aMetalloendopeptidases$xantagonists & inhibitors.$0https://id.nlm.nih.gov/mesh/D008666Q000037
650 12 $aMetalloendopeptidases$xmetabolism.$0https://id.nlm.nih.gov/mesh/D008666Q000378
650 22 $aExtracellular Matrix$xenzymology.$0https://id.nlm.nih.gov/mesh/D005109Q000201
650 22 $aNeoplasms$xdrug therapy.$0https://id.nlm.nih.gov/mesh/D009369Q000188
650 4 $aAntineoplastic agents.
650 4 $aMetalloproteinases$xInhibitors$xTherapeutic use.
650 4 $aExtracellular matrix proteins$xInhibitors$xTherapeutic use.
700 1 $aClendeninn, Neil J.$0http://id.loc.gov/authorities/names/n00008803
700 1 $aAppelt, Krzysztof.$0http://id.loc.gov/authorities/names/n00008802
830 0 $aCancer drug discovery and development.$0http://id.loc.gov/authorities/names/n88538383
852 00 $boff,hsl$hRC271.M43$iM38 2001